Immunomedics, Inc. Announces 4 Presentations on Epratuzumab at 2013 American College of Rheumatology Annual Meeting
Published: Oct 25, 2013
MORRIS PLAINS, N.J., Oct. 25, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 4 presentations on studies of epratuzumab in systemic lupus erythematosus (SLE) will be presented at the 2013 Annual Meeting of the American College of Rheumatology (ACR) to be held in San Diego, CA, from October 26 – 30, 2013.
Help employers find you! Check out all the jobs and post your resume.